Barclays PLC Increases Investment in Protagonist Therapeutics,
February 8, 2023
Trending News 🌥️
Barclays PLC has recently announced that it has significantly increased its investment in Protagonist Therapeutics ($NASDAQ:PTGX), Inc., a biopharmaceutical company focused on discovering, developing and commercializing novel peptide-based drugs. Protagonist Therapeutics is focused on developing treatments for diseases that have limited treatment options or no available treatments. The company’s pipeline of peptide-based drugs includes treatments for ulcerative colitis, Crohn’s disease, anemia, and other rare diseases. It has several clinical-stage programs and several more in preclinical stages of development. This is the first time that Barclays PLC has invested in the company and it is expected to help accelerate the development of Protagonist Therapeutics’ pipeline.
Barclays PLC’s investment also provides a much needed boost to the company’s share price, which has been under pressure in recent months due to delays in the development of its products. Overall, the increased investment from Barclays PLC is a strong indication that Protagonist Therapeutics is on the right track with its development of novel peptide-based drugs. This should provide investors with confidence that the company’s pipeline has potential and that the company is well positioned to capitalize on these potential treatments in the future.
Price History
Barclays PLC recently announced an increase in their investment in Protagonist Therapeutics, Inc. At the time of writing, news of the increase in investment appears to be mostly positive. On Monday, Protagonist Therapeutics stock opened at 14.3 and closed at 15.0, up by 4.4% from the previous closing price. The increase in investment from Barclays PLC is seen as a major vote of confidence in the future of Protagonist Therapeutics. The company has made considerable progress in developing treatments for various diseases, including ulcerative colitis, hereditary angioedema, and alpha-1 antitrypsin deficiency. Protagonist Therapeutics’ current pipeline includes several promising Phase 2 and Phase 3 clinical trials that could potentially result in groundbreaking treatments for these conditions. The increased investment from Barclays PLC is also seen as a sign that the company is on the right track in terms of their strategic direction and long-term plans.
Protagonist Therapeutics has recently implemented several cost-saving measures to help maximize their potential returns, and has also expanded their portfolio of products to include treatments for other conditions, such as Crohn’s disease. Overall, the increased investment from Barclays PLC is seen as a positive sign for the future of Protagonist Therapeutics. With continued research and development, the company is poised to make further advances in developing treatments for a variety of conditions. The increased investment from Barclays PLC is a welcome endorsement of the company’s future prospects and potential. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Protagonist Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 35.2 | -130.11 | -369.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Protagonist Therapeutics. More…
| Operations | Investing | Financing |
| -103.44 | 115.4 | 20.46 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Protagonist Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 282.17 | 38.56 | 4.95 |
Key Ratios Snapshot
Some of the financial key ratios for Protagonist Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -4.0% | – | -373.8% |
| FCF Margin | ROE | ROA |
| -296.5% | -32.1% | -29.1% |
Analysis
GoodWhale has conducted an analysis of PROTAGONIST THERAPEUTICS‘s wellbeing. The Star Chart indicates that PROTAGONIST THERAPEUTICS is strong in asset, growth, and weak in dividend and profitability. To further evaluate PROTAGONIST THERAPEUTICS’s health, the company’s cashflows and debt were analyzed which led to an intermediate health score of 5/10. This score suggests that PROTAGONIST THERAPEUTICS is likely to pay off its debt and have sufficient funds to cover its future operations. PROTAGONIST THERAPEUTICS has been classified as a ‘cheetah’ company, which typically achieves high revenue or earnings growth but is considered less stable due to lower profitability. Such companies may be attractive to investors who are looking for potential growth opportunities with a higher risk-return profile. These investors may be willing to invest in the company despite the fact that it is not as profitable as other firms in the industry. Additionally, cheetah companies may also be of interest to those investors looking for a more aggressive approach to investing. In conclusion, PROTAGONIST THERAPEUTICS has been identified by GoodWhale as a ‘cheetah’ company with an intermediate health score of 5/10. As such, the firm may be of interest to investors seeking potential growth opportunities with a higher risk-return profile. More…
Peers
The company’s competitors include LogicBio Therapeutics Inc, Landos Biopharma Inc, and IO Biotech Inc.
– LogicBio Therapeutics Inc ($NASDAQ:LOGC)
LogicBio Therapeutics Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases. The company’s lead product candidate is LB-1001, which is in clinical development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID). The company has a market cap of $67.57 million and a return on equity of -82.33%. LogicBio Therapeutics is headquartered in Boston, Massachusetts.
– Landos Biopharma Inc ($NASDAQ:LABP)
Landos Biopharma Inc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
Landos Biopharma Inc has a market cap of 14.4M as of 2022, a Return on Equity of -64.92%. The company is dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat serious unmet medical needs, primarily in oncology. The company has a market capitalization of $72.04 million and a negative return on equity of 20.77%. Incyte is headquartered in Wilmington, Delaware, and has operations in the United States, Europe, and Asia.
Summary
Barclays PLC recently made an increased investment in Protagonist Therapeutics, Inc. at the time of writing. The news has been mostly positive and the stock price has moved upward as a result. Analysts suggest that investing in Protagonist Therapeutics is a good option for investors as the company has seen positive growth in recent months and is expected to continue to show positive results in the future.
This could mean potential returns for investors if they choose to invest in the company. Investors should research the company thoroughly before investing to ensure their portfolio is diversified and the risks are understood.
